<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051167</url>
  </required_header>
  <id_info>
    <org_study_id>TT1-2007</org_study_id>
    <secondary_id>2007-000460-24</secondary_id>
    <nct_id>NCT01051167</nct_id>
  </id_info>
  <brief_title>Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer</brief_title>
  <acronym>CEBIFOX</acronym>
  <official_title>Bi-weekly Cetuximab Combined With FOLFOX-6 as First-line Treatment in Metastatic Colorectal Cancer Patients With Wild-type K-ras Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Martin Schuler, Prof. Dr. med.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cetuximab is normally given as a weekly schedule in the therapy of patients with metastatic&#xD;
      colorectal cancer.&#xD;
&#xD;
      In order to improve the convenience for the patients in first line-therapy this study will&#xD;
      evaluate the efficacy and safety of a bi-weekly combination of cetuximab with FOLFOX.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For years the effective treatment of advanced colorectal carcinoma (CRC) was limited to&#xD;
      fluorouracil (5-FU). Combination of 5-FU or a 5-FU analog with oxaliplatin, which has some&#xD;
      antitumor activity as a single agent, shows synergistic activity. Combining oxaliplatin with&#xD;
      a twice monthly folinic acid/5-FU schedule leads to a further improvement in first-line&#xD;
      treatment of advanced CRC thus emerging to a standard regimen in first-line therapy of&#xD;
      metastatic CRC.&#xD;
&#xD;
      Cetuximab is normally given as a weekly schedule. As recently shown a biweekly schedule with&#xD;
      500 mg/m² instead of the weekly standard regimen (initial dose of 400 mg/m² followed by 250&#xD;
      mg/m² every week) exhibits similar pharmacokinetic results with a comparable efficacy.&#xD;
&#xD;
      In order to improve the convenience for the patients, this study will evaluate the efficacy&#xD;
      and safety of a bi-weekly combination of cetuximab with FOLFOX. Out of the various FOLFOX&#xD;
      regimens the most convenient FOLFOX-6 schedule is chosen for the study, which has been tested&#xD;
      before in two studies in combination with the standard weekly schedule of cetuximab. Recent&#xD;
      data suggest a decreased efficacy of cetuximab in patients bearing a k-ras mutation in their&#xD;
      CRC. Therefore only patients with no evidence for a mutated k-ras gene in the colorectal&#xD;
      carcinoma cells will be included in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate (RECIST-Criteria)</measure>
    <time_frame>Every 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives: Safety, Quality of life</measure>
    <time_frame>Every 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab + Folfox-6-regime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:&#xD;
Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks</description>
    <arm_group_label>Cetuximab + Folfox-6-regime</arm_group_label>
    <other_name>Erbitux®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven metastatic colorectal cancer&#xD;
&#xD;
          -  Molecular test showing no mutation in the k-ras gene of colorectal carcinoma cells&#xD;
&#xD;
          -  Male and female subjects ≥ 18 years of age&#xD;
&#xD;
          -  1st occurrence of metastatic disease (not curatively resectable)&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Presence of at least 1 bi-dimensionally measurable index lesion (not in an irradiated&#xD;
             area)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at study entry&#xD;
&#xD;
          -  Adequate bone marrow reserve:&#xD;
&#xD;
        leucocytes ≥ 3.0 x 109/l with neutrophils ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l,&#xD;
        haemoglobin ≥ 6.21 mmol/l (10 g/dl)&#xD;
&#xD;
          -  Aspartate-aminotransferase (ASAT) and alanine-aminotransferase (ALAT) ≤ 2.5 x upper&#xD;
             reference range, in case of liver metastasis ≤ 5 x upper reference range&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x upper reference range&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x upper reference range&#xD;
&#xD;
          -  Negative pregnancy test for female and effective contraception for both male and&#xD;
             female subjects if the risk of conception exists&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence for a mutation of the k-ras gene in the colorectal carcinoma cells&#xD;
&#xD;
          -  Previous exposure to epidermal growth factor receptor-targeting therapy&#xD;
&#xD;
          -  Prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  Prior oxaliplatin based adjuvant chemotherapy or &lt; 6 months after end of adjuvant&#xD;
             treatment&#xD;
&#xD;
          -  Other previous malignancy with exception of a history of a previous curatively treated&#xD;
             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix&#xD;
&#xD;
          -  Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug&#xD;
             in the 30 days before registration&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy or hormone therapy not indicated in this&#xD;
             study protocol&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 ml/min&#xD;
&#xD;
          -  Known hypersensitivity reaction to any of the components of study treatment&#xD;
&#xD;
          -  Pregnancy (absence to be confirmed by ß-human chorionic gonadotropin (hCG) test) or&#xD;
             lactation period&#xD;
&#xD;
          -  Clinically relevant coronary artery disease, history of myocardial infarction in the&#xD;
             last 12 months, or high risk of uncontrolled arrhythmia&#xD;
&#xD;
          -  Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease&#xD;
&#xD;
          -  Brain metastasis (known or suspected)&#xD;
&#xD;
          -  Medical or psychological conditions that would not permit the subject to complete the&#xD;
             study or sign informed consent&#xD;
&#xD;
          -  Known alcohol or drug abuse&#xD;
&#xD;
          -  Participation in another clinical study within the 30 days before registration&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Significant disease which, in the investigator's opinion, would exclude the patient&#xD;
             from the study&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schuler, Prof.Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>University of Duisburg-Essen Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Duisburg-Essen Medical School</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp von Bohlen und Halbach Krankenhaus gGmbH</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prosper Hospital Recklinghausen</name>
      <address>
        <city>Recklinghausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Martin Schuler, Prof. Dr. med.</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

